BENDAMUSTINE IN HODGKIN LYMPHOMA
|
|
- Mildred Lester
- 6 years ago
- Views:
Transcription
1 CONVEGNO REGIONALE SIE DELEGAZIONE REGIONALE EMILIA ROMAGNA ATTUALITA IN EMATOLOGIA BOLOGNA BENDAMUSTINE IN HODGKIN LYMPHOMA Dott.ssa Cinzia Pellegrini Istituto di Ematologia e Oncologia Medica "L&A" Sèragnoli
2 Bendamustine First synthesized in the 1960 s in Jena, in the former East Germany. Limited data published during the initial period of investigation Used in the treatment of NHL,CLL, Multiple Myeloma, Hodgkin s disease and solid tumors, i.e. Breast cancer and small cell lung cancer Effective in cell lines that are refractory to alkylating agents Only partial cross-resistance with melphalan and cyclophosphamide as a rational for using bendamustine in previously treated patients with low-grade lymphoma
3 Bendamustine Extensive DNA-damage Like other alkylating agents, it causes intra-stand and inter stand cross-links between DNA bases Tageja N, et al. Cancer Chemother Pharmacol (2010) 66: More durable and more extensive DNA-damage than other alkylating agents. It is also associated with a relatively slower repair of DNA damage than other alkylating agents.
4 Bendamustine Apoptosis via a TP53-dependent mechanism; Inhibition of mitotic checkpointsregulating genes, such as CCNB1, As a result of this distinctive activity AURKA profile, and Bendamustine PLK1, this drugs also show limited cross-resitance with agents triggers usually a complex employed phenomenon, for upfront and salvage treatments of HD known including as mitotic anthracyclines, catastrophe, that dacarbazina, cyclophosphamide, ifosfamide, activated non melphalan apoptotic cell and death carmustine. pathway in tumor cells Activates an exonuclease-1 (EXO1) Dna repair Leoni L.M. et al, Clin Canc Res 2008; 14 (1) January 1, 2008
5 Bendamustine: Development in HL
6 Bendamustine (Cytostasan) in HD:PALEOZOIC Author n Prev. Rx Herold M et al. (1999) 80 None CVPP vs CVPP/DVBB Dose/ schedule CVPP/DVBB (DNR, BLM, VCR, B) B: 30 mg/m2, d 8-12, q28 ORR 75% vs 87.5% Herold M et al. (1987) Herold M et al. (1998) Hoche D et al. (1984) 43 None CVPP/ ABVB CVPP/ ABVB 100 None CVPP/ABVC vs CVPP/ABVB 73 CVPP DBVCy[B] vs ABVD B: 30 mg/m2, D 8-12, q28 B: 30 mg/m2, D 8-12, q28 DBVCy (DNR, BLM, VCR, Cy) Cy: 50 mg/m2, D 1-5, q 28 93% CR: 81% PR: 12% CR: 81% vs CR: 88% 69% vs 83% Herold M, et al. Med Klin 1987;82: Herold M, et al, Onkologie 1999; 22: Herold, M., et al., Leuk Lymphoma, (Suppl. 1). Hoche D, Arch GeschwulsVorsch 1984;4:
7 Bendamustine in HD: MESOZOIC Case reports Author n Previous Rx Dose/ schedule Response D Elia GM et al. (2010) 1 ABVD, BEACOPP, IEV, DHAP, PROVECIP, RT 90 mg/m2, D1+D2 q 4w CR; 6.0 mo.s Magyari F et al. (2011) 1 ABVD, IGEV, ASCT, R-miniBEAM 90 mg/m2 D1+D2 q 4w + Rituximab CR: > 8.0 mo.s Mian M et al. (2013) 2 ABVD, Stanford V BEACOPP, ASCT, allo-sct 90 mg/m2 D1+D2 q 4w + Rituximab + DLI 2 CR: >12 mo.s 9.0 mo.s D Elia GM et al. Leuk Res 2010; 34:e300-1 Magyari F et al. Hematol Oncol Oct 28 [Epub]. Mian M. et al. Ann Hematol (2013) 92:
8 Bendamustine in RR-HL: Fase II Study Moskowitz A. et al. JCO :
9 Bendamustine in RR-HL: Fase II Study Elegibility criteria Biopsy-confirmed relapsed/ refractory classical HL Failure of ASCT or inelegibility Previous Allo-SCT was allowed if relapsed was>6 months from transplantation Patients deemed potentially elegible for Allo-SCT at the time of enrollment were simultaneously offered enrollment onto parallel intent-to-treat study evaluating allosct in relapsed/refractory HL 120 mg/m 2 (d1+d2 ) q28 A total of 6 cycles was planned Moskowitz A. et al. JCO :
10 Bendamustine in RR-HL: Fase II Study Safety Toxicity and Treatment Reduction and Delays Biopsy-confirmed relapsed/ refractory classical HL Failure of ASCT or inelegibility Previous Allo-SCT was allowed if relapsed was>6 months from transplantation Moskowitz A. et al. JCO : Moskowitz A. et al. JCO :
11 Bendamustine in RR-HL: Fase II Study Activity History of ASCT History of Allo-SCT Refractory disease No impact on likelihood of responding to Bendamustine Moskowitz A. et al. JCO :
12 Bendamustine in RR-HL: Fase II Study Activity 68% Achieved Tumor Regression Moskowitz A. et al. JCO :
13 Bendamustine in RR-HL: Fase II Study Allo-SCT Outcome - 5 Patients (20%) underwent allo-sct directly after treatment with Bendamustine - The median number of cycles of B. before allosct was 4-4 pt had achieved CRs and 1 PR at time of allosct The median follow-up of surviving patients was 3 years - Since undergoing allo-sct, 2 pt have remained in remission 19 and 31 months and 3 pt relapsed at 100 days, 16 months and 21 months after Allo-SCT PFS: 5.2 MONTHS Moskowitz A. et al. JCO :
14 Bendamustine in RR-HL: Fase II Retrospective Study the Real Life Author n Pts. Dose/ schedule Response Corazzelli G et al. (Br J Haematol 2012) Anastasia et al. (ASH 2012) 1 n mg/m2, D1+D2 q21/ mg/m2, D1+D2 q21/28 90 mg/m2, D1+D2 q28 1 n mg/m2, D1+D2 q mg/m2, D1+D2 q28 90 mg/m2, D1+D2 q28 ORR: CR: mdr: ORR: CR: mdr: mdr: median duration of response Corazzelli G, et al. Br J Haematol 2013, 160, Anastasia A, et al. ASH 2012
15 Bendamustine in RR-HL: Retrospective Study
16 Bendamustine in RR-HL: Retrospective Study Real life: 41 pts. 58%: 120 mg/m 2 (d1+2 ) q21/28 15%: 100 mg/m 2 (d1+2 ) q21/28 27%: 90 mg/m 2 (d1+22 ) q28 85%: at least 3 courses 51 %: 6 courses Median ADI*: 60.2 mg/m 2 /week (r ) 25 percentile: 50.1 mg/m 2 /wk 75 percentile: 68.2 mg/m 2 /wk *First 3 courses Corazzelli G. et al. British Journal of Haematology, 2013, 160,
17 Bendamustine in RR-HL: Retrospective Study Corazzelli G. et al. British Journal of Haematology, 2013, 160,
18 Bendamustine in RR-HL: Retrospective Study Corazzelli G. et al. British Journal of Haematology, 2013, 160,
19 Bendamustine in RR-HL: Retrospective Study 2 years: 20.5% Madian PFS: 11.1 months Median PFS was not influenced by disease status relapsed/ refractory, previous single vs tandem SCT,, and ADI of bendamustine (60 mg/ mq per week or > 2 years OS:47% Madian PFS: 11.1 months Corazzelli G. et al. British Journal of Haematology, 2013, 160,
20 Bendamustine for Relapsed/Refractory Classical Hodgkin Lymphoma After High Dose Chemotherapy and or Allogeneic Transplant: A Study of Fondazione Italiana Linfomi (FIL) Antonella Anastasia, MD 1*, Carmelo Carlo-Stella, MD 2, Paolo Corradini, MD 3, Flavia Salvi 4*, Chiara Rusconi 5*, Alessandro Pulsoni 6*, Stefan Hohaus, MD 7*, Patrizia Pregno 8*, SimoneEa Viviani, MD 9*, Ercole Brusamolino, MD 10,11*, Stefano Luminari 12*, Laura Giordano, MD 13* and Armando Santoro, MD 14* 73 patients rr-hl after ASCT (n = 46) or ASCT+allo-SCT (n = 23) 120 mg/m 2 (d1+2 ) q mg/m 2 (d1+2 ) q28 90 mg/m 2 (d1+2 ) q28 ORR: 58% (25% CR; 33% PR) Median time to response: 3.4 months (r ) Median response duration: 5.1 months (r ) Severe hematologic toxicity was observed in 20/69 pts (29%); grade 3-4 neutropenia, thrombocytopenia and anemia were observed in 11 (16%), 11(16%) and 4(6%)pts, respec^vely.
21 Bendamustine in RR-HL
22 Bendamustine in RR-HL N. Pts ORR CR Cycles Median PFS Pivotal (1-6) 5.2 Italian NPP1 French NPP Italian NPP (1-8) (1-12) 5, (1-12) 10 PFS % (Unit : %) median DFS <20% 5.mos 21% 9 mo.s 11% - 24% 5.1 mo.s Responses mostly achieved between 3-4 cycles Remarkable early response rate but relative short duration Strategies for early consolidation or maintenance need to be devised Moskowitz AJ, J Clin Oncol 2013, 31:456; Ghesquieres H, Leuk & Lymphoma, :2399; Corazzelli G, Br J Haematol 2013, 160: 207; Anastasia A, 54th ASH Meeting 2012,Abstr 3652
23 Agents evaluating in HL relapsing after ABMT
24
25 Bendamustine in combination Ongoing Phase I/II trials drugs schedule Sponsor NTC Gemcitabine + Bendamustine G. (dose NR) on d1 B (escalation) on dd 1-2, every 3-4 weeks Ohio University NTC Brentuximab Ved + Bendamustine BV 1,2!1,8mg/kg d1 B 60"100mg/m 2 dd 1-2 every 3 weeks British Columbia Cancer Agency, Canada NCT Lenalidomide + Bendamustine Lena 10"25mg x 28 dd B 60 mg dd 1,8,15 every 4 weeks Istituto Tumori Fond. Pascale Napoli NTC Brentuximab Ved + Bendamustine BV 1.8 mg/kg d1 B 90 mg/m2 dd 1 and 2, every 3 weeks Seattle Genetics USA
26 NTC LEBEN Bayesian Phase I/II An open non-randomized multicenter Phase 1/2 dose finding study of Lenalidomide in Combination with Bendamustine (LeBen) in relapsed and primary refractory Hodgkin Lymphoma Primary Endpont: Dose-finding at best Trade-off for Efficacy / Toxicity (ie, CR+PR vs Grade>3 AE) Dose Level Lenalidomide Dose Bendamustine Secondary Endpoints: ORR (CR+PR), EFS, PFS 1 10 mg dd mg dd mg dd mg/m2 dd 1,8,15 Hematology- Oncology and Stem Cell Transplanta^on Unit, Is^tuto Nazionale Tumori, Fond. Pascale, IRCCS Napoli, Italy 4 25 mg dd1-28
27 LeBen for RR-Hodgkin s Lymphoma
28 NTC LEBEN Bayesian Phase I/II LEBEN x 2 primary endpoints evaluation Best (EFF/ TOX) Trade-off [CR+PR] vs [Grade>3 AE ] CR, PR, SD Best dose LEBEN x 4 secondary endpoints (ORR, EFS) evaluation PD Off-study
29 LeBen for RR-Hodgkin s Lymphoma
30 LeBen for RR-Hodgkin s Lymphoma
31 LeBen for RR-Hodgkin s Lymphoma
32
33 Anastasia A. et al POSTER SESSSION ASH 2012
34 Anastasia A. et al POSTER SESSSION ASH 2012
35 Mobilization of Hematopoietic stem cells by a Bendamustinecontaining regimen in Hodgkin s Lymphoma Dati sui primi 14 pazienti: nessun fallimento Raccolta media: 7.8 x10 6 CD34/kg (range Numero mediano di procedure: 1 (range 1-2) Anastasia A. et al POSTER SESSSION ASH 2012
36 Bendamustine in Hodgkin Lymphoma: Phase II studies & real life retrospective studies Significant response rate Favorable toxicity profile: - manageable/expected hematologic toxicity (thrombocytopenia, infection) -mild non-hematologic toxicity Adequate response duration Response independent from prior: - chemosensitivity status, - ASCT, allo-sct - Bendamustine ADI Short time to best response (2-4 cycles) Early CRs mantained Early PRs do not usually upgrade
37 Bendamustine in Hodgkin Lymphoma Does it work? Yes, it does! How it works? May be differently than in B-NHL (???) Can we combine it with other agents in rr-hl? Yes, we can! How? Why? 1.To cytoreduce preallosct 2. To palliate 3. As a platform for combination with target-based agents Image: L. Leoni. Clinical Advances in Hematology & Oncology 2011,9 (S 19),
38
Bendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service
Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)
More informationChemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL
Lymphoma & Myeloma 2015 Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Jeremy S. Abramson, MD Relevant Disclosure Consulting for Seattle
More informationConfronto Real world e studi registrativi
Confronto Real world e studi registrativi V. Pavone San Giovanni Rotondo 8 Novembre 2018 U.O Ematologia Az.Osp.Card.G.Panico MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY
More informationLinfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP
Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationAHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital
AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationWhat is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin
What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin Alison Moskowitz, MD Assistant Attending, Lymphoma Service Memorial Sloan Kettering
More informationThe Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma
The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma Anna Sureda Haematology Department Hospital Universitari Quirón Dexeus Barcelona, Spain 9 th Educational Course on Lymphomas
More informationInterim PET Hodgkin s Disease. Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal
Interim PET Hodgkin s Disease Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal Why is this a Question? Early Advanced ipet ABVD + RT ABVD Pos Neg ABVD Beacopp Escalation Salvage Deescalation Talk outline
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationFerrata Storti Foundation
ARTICLES Introduction Hodgkin s Lymphoma Brentuximab vedotin in relapsed/refractory Hodgkin s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials
More informationThe Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma
The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma Anna Sureda Haematology Department Institut Catala d Oncologia Hospital Duran I Reynals Barcelona, Spain 10 th Educational
More informationBrentuximab, Nivolumab: L esperienza Real Word della REP. Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase
Brentuximab, Nivolumab: L esperienza Real Word della REP Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY IMPROVE
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationKamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA
Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory
More informationLinfoma di Hodgkin Tra/amento dei pazien4 ricadu4
Linfoma di Hodgkin Tra/amento dei pazien4 ricadu4 Simonetta Viviani SC Ematologia e Trapianto di Midollo osseo Dichiarazione Relatore: SimoneGa Viviani Posizione di dipendente in aziende con interessi
More informationInotuzumab Ozogamicin in ALL. Hagop Kantarjian M.D. May 2016 Bologna, Italy
Inotuzumab Ozogamicin in ALL Hagop Kantarjian M.D. May 2016 Bologna, Italy Immuno Oncology in ALL Monoclonals + cytotoxic agents e.g.inotuzumab Bispecific monoclonals (CD3 + CD19) e.g.blinatumomab Modified
More informationA CME-certified Oncology Exchange Program
A CME-certified Oncology Exchange Program Jointly provided by Potomac Center for Medical Education and Rockpointe Supported by an educational grant from Seattle Genetics, Inc. Re-treatment with BV Bartlett
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationNovel Therapeutic Targets for Hodgkin Lymphoma
Hodgkin Lymphoma:...Therapeutic Biology Novel Therapeutic Targets for Hodgkin Lymphoma Antonello Pinto Hematology-Oncology and Stem Cell Transplantation Unit Department of Hematology National Cancer Institute,
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationPeripheral T-Cell Lymphoma. Pro auto. Peter Reimer. Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation
Peripheral T-Cell Lymphoma Pro auto Peter Reimer Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation Kliniken Essen Süd, Evang. Krankenhaus Essen-Werden ggmbh COSTEM, Berlin 09.09.2011
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationHow to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma
How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma Dr. Guillermo Rodríguez García Hospital Universitario Virgen Macarena Hospital Universitario Virgen del
More informationPET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD
PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies
More informationWhat is the best approach to the initial therapy of PTCL? standards of treatment? Should all
What is the best approach to the initial therapy of PTCL? standards of treatment? hould all Jia Ruan, M.D., Ph.D. Center for Lymphoma and Myeloma Weill Cornell Medical College New York Presbyterian Hospital
More informationImmune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust
Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationGerman Hodgkin Study Group
German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Avoiding Relapse of Hodgkin Lymphoma: Have We Moved The Needle? Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of
More informationPembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationGruppo Italiano Terapie Innovative nei Linfomi (G.I.T.I.L.) Dr. Andrea Gallamini S.C. Ematologia Az. Ospedaliera S. Croce e Carle, Cuneo
Sponsor Principal Investigator Protocol Coordinators Coordinating Centre Writing committee CRO Gruppo Italiano Terapie Innovative nei Linfomi (G.I.T.I.L.) Dr. Andrea Gallamini S.C. Ematologia Az. Ospedaliera
More informationNew Agents Beyond Brentuximab vedotin for Hodgkin Lymphoma. Stephen M. Ansell, MD, PhD Professor of Medicine Mayo Clinic
New Agents Beyond Brentuximab vedotin for Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Mayo Clinic Disclosures for Stephen Ansell, MD, PhD In compliance with ACCME policy, Mayo Clinic
More informationFollicular Lymphoma 2016:
Follicular Lymphoma 2016: Evolving Management Strategies Randeep Sangha, MD Medical Oncology, Cross Cancer Institute Associate Professor, University of Alberta Edmonton, AB Disclosures I have no actual
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationBendamustine: A Transversal * Chemotherapy Agent
Bendamustine: A Transversal * Chemotherapy Agent Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, D.C., USA *Def Cutting across two lines, intersecting
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Robert Chen, MD Associate Professor of Medicine Co-Leader of Lymphoma Disease Team Associate Director of Toni Stephenson Lymphoma Center City of Hope National Medical
More informationMantle Cell Lymphoma: Update in Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency
Mantle Cell Lymphoma: Update in 2015 Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency Disclosures Research funding: Roche provides research funding to support the Centre for Lymphoid Cancer
More informationUpdates in T cell Lymphoma
Winship Cancer Institute of Emory University Updates in T cell Lymphoma Mary Jo Lechowicz August 2014 Objectives Update current care for patients with Peripheral T cell Non Hodgkin lymphomas (PTCL) upfront
More informationAngioimmunoblastic T-cell lymphoma: nobody knows what to do...
Angioimmunoblastic T-cell lymphoma: nobody knows what to do... Felicitas Hitz, Onkologie/Hämatologie St.Gallen SAMO Lucerne 17.9.2011 : Problems PTCL are rare diseases with even rarer subgroups Difficulte
More informationABVD versus BEACOPP arguments for ABVD. Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS
ABVD versus BEACOPP arguments for ABVD Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS DISCLOSURES HONORARIAS: Takeda, roche GRANT RESEARCH : Millenium Takeda, AMGEN ABVD the standard chemotherapy
More informationDr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK
EMBT LWP 2017-R-05 Research Protocol: Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma. A retrospective analysis of the LWP-EBMT registry. Principle
More informationPomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
More informationDr. Andrea Gallamini - Hematology Department Azienda Ospedaliera S. Croce e Carle Cuneo Italy
High-dose sequential chemotherapy (HDS) followed by autologous stem cell transplantation (ASCT) in relapsed/refractory Hodgkin s lymphoma. Long term results. Dr. Andrea Gallamini - Hematology Department
More informationHodgkin Lymphoma Review of characteristics and treatment of elderly patients
Hodgkin Lymphoma Review of characteristics and treatment of elderly patients Boris Böll M.D. German Hodgkin Study Group (GHSG) University Hospital Cologne OS of HL patients in all stages 1960-1967 Courtesy
More informationCPAG Summary Report for Clinical Panel 1608 Bendamustine for relapsed multiple myeloma
MANAGEMENT IN CONFIDENCE CPAG Summary Report for Clinical Panel 1608 Bendamustine for relapsed multiple myeloma The Benefits of the Proposition (Grade of Evidence to be left blank) No Outcome measures
More informationNovita da EHA 2016 Copenhagen Linfomi
Firenze, 16th September 2016 Marco Ladetto MD, Az Osp Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy EU Novita da EHA 2016 Copenhagen Linfomi THREE QUESTIONS TO ADDRESS: 1. Is ASCT still the
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationBENDAMUSTINE + RITUXIMAB IN CLL
BENDAMUSTINE + RITUXIMAB IN CLL Barbara Eichhorst Bologna 13. November 2017 CONFLICT OF INTERESTS 1. Advisory Boards Janssen, Gilead, Roche, Abbvie, GSK 2. Honoraria Roche, GSK, Gilead, Janssen, Abbvie,
More informationOptions in Mantle Cell Lymphoma Therapy
Options in Mantle Cell Lymphoma Therapy Carlo Visco, MD Dept of Cell Therapy and Hematology San Bortolo Hospital, Vicenza, taly My Disclosures: ADVSOR OR ADVSORY BOARDS: Lundbeck Canada nc, Celgene Europe,
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationDoes BV as part of salvage impact outcome?
Does BV as part of salvage impact outcome? Craig Moskowitz, MD Steven A. Greenberg Chair in Lymphoma Research Member, Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Medical College
More informationHaemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY. Development and clinical experience Monique Minnema, hematologist
Haemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Development and clinical experience Monique Minnema, hematologist Consultancy for disclosures Amgen, Celgene, Jansen Cilag, BMS, Takeda Immune
More informationBrentuximab Vedotin in Lymphomas
New Drugs In Hematology Brentuximab Vedotin in Lymphomas Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 9:15-9:45 a.m U.S. Cancer Statistics 2016 300.000
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationTreatment Nodal Marginal Zone Lymphoma
Workshop : Indolent lymphomas Treatment Nodal Marginal Zone Lymphoma Catherine Thieblemont Hôpital Saint-Louis, Paris - France Bologna 16th, 2017 Ø No standardized treatment Ø Similarly treated as FL Treatment
More informationJonathan W Friedberg, MD, MMSc
I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer
More informationUpdates in the Treatment of Non-Hodgkin Lymphoma: ASH Topics
Updates in the Treatment of Non-Hodgkin Lymphoma: ASH 2008 Joseph Tuscano, M.D. UC Davis Cancer Center 1 Topics Mantle Cell Lymphoma What is the standard of care for younger patients? (abstracts 581, 769,
More informationBrentuximab Vedotin. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center
Brentuximab Vedotin Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center U.S. Cancer Statistics 2016 300.000 249.260 224.390 200.000 180.890 Incidence 100.000 95.270 76.960
More informationAdvanced stage HL The old and new match: BEACOPP
27.03.2015 1 Advanced stage HL The old and new match: BEACOPP Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Which answer is wrong? For patients with advanced stage HL, treatment
More informationMMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE
Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar
More informationManaging patients with relapsed follicular lymphoma. Case
Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell
More informationStem Cell Transplant for Myeloma: The New Landscape
Stem Cell Transplant for Myeloma: The New Landscape Sergio A. Giralt, MD Chief, Adult Bone Marrow Transplant Service Division of Hematologic Oncology Department of Medicine Memorial Sloan-Kettering Cancer
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationIs there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes
Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe «Pathologie
More informationVenetoclax in MCL. Prof. Le Gouill Nantes Medical University, France
Venetoclax in MCL Prof. Le Gouill Nantes Medical University, France Evasion of Apoptosis, or Cell Death, is 1. Resisting Cell Death 2. Sustained angiogenesis for growth and survival (primarily solid tumors)
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationABVD or BEACOPP for advanced Hodgkin lymphoma. Not to BEACOPP. Massimo Federico University of Modena and Reggio Emilia Italy
ABVD or BEACOPP for advanced Hodgkin lymphoma Not to BEACOPP Massimo Federico University of Modena and Reggio Emilia Italy What is the best Induction Therapy for Advanced Hodgkin Lymphoma? How to treat
More informationTREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
More informationbrentuximab vedotin (Adcetris ) 50mg powder for concentrate for solution for infusion SMC No. (845/12) Takeda UK Ltd
brentuximab vedotin (Adcetris ) 50mg powder for concentrate for solution for infusion SMC No. (845/12) Takeda UK Ltd 05 September 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationBrentuximab vedotin in Relapsed Primary Mediastinal Large B-Cell Lymphoma: Results from a Phase 2 Clinical Trial
Blood First Edition Paper, prepublished online March 6, 2017; DOI 10.1182/blood-2017-01-764258 Letter To Blood Brentuximab vedotin in Relapsed Primary Mediastinal Large B-Cell Lymphoma: Results from a
More informationHodgkin Lymphoma Status of the art of treatment
11.05.2016 1 Hodgkin Lymphoma Status of the art of treatment Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Question No 1: Which statement regarding 1 st line treatment of early
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More informationElderly Patients with Hodgkin s Lymphoma: FIL experience. Massimo Federico University of Modena and Reggio Emilia
Elderly Patients with Hodgkin s Lymphoma: FIL experience Massimo Federico University of Modena and Reggio Emilia RESULTS OF VbMp CHEMOTHERAPY REGIMEN IN ELDERLY PATIENTS WITH HODGKIN DISEASE: THE GISL
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationChallenges in the Treatment of Follicular Lymphoma
Challenges in the Treatment of Follicular Lymphoma Prof. Michele Ghielmini Clinical Director Oncology Institute of Southern Switzerland Bellinzona ESMO guidelines 2014 (simplified) Low tumor burden High
More informationBackground. Outcomes in refractory large B-cell lymphoma with traditional standard of care are extremely poor 1
2-Year Follow-Up and High-Risk Subset Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma Abstract 2967 Neelapu SS, Ghobadi A, Jacobson
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationClinical Overview: MRD in CLL. Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel
Clinical Overview: MRD in CLL Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel m.ritgen@med2.uni-kiel.de Remission in CLL Clinical criteria (NCI->WHO) Lymphadenopathy Splenomegaly Hepatomegaly
More informationHaploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy
Haploidentical Transplants for Lymphoma Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy HODGKIN NON HODGKIN Non Myelo Ablative Regimen Luznik L et al BBMT 2008 Comparison of Outcomes
More information